NO20092025L - Reduksjon av overvekt eller fedme - Google Patents

Reduksjon av overvekt eller fedme

Info

Publication number
NO20092025L
NO20092025L NO20092025A NO20092025A NO20092025L NO 20092025 L NO20092025 L NO 20092025L NO 20092025 A NO20092025 A NO 20092025A NO 20092025 A NO20092025 A NO 20092025A NO 20092025 L NO20092025 L NO 20092025L
Authority
NO
Norway
Prior art keywords
reduction
overweight
obesity
weight gain
bgp
Prior art date
Application number
NO20092025A
Other languages
English (en)
Inventor
Kalman Takacs
Balazs Suemegi
Peter Literati Nagy
Zoltan Szilvassy
Kalman Tory
Laszlo Vigh
Jozsef Mandl
Sandor Bernath
Attila Kolonics
Gabor Balogh
Janos Egri
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Publication of NO20092025L publication Critical patent/NO20092025L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Fats And Perfumes (AREA)

Abstract

Oppfinnelsen angår anvendelse av O-(3-piperidino-2-hydroksy-1-propyl)-nikotinsyre amidoxim eller et farmasøytisk akseptabelt syreaddisjonssalt derav for hindring av abnormal kroppsvektøkning eller reduksjon av overvekt eller fedme.
NO20092025A 2006-11-02 2009-05-25 Reduksjon av overvekt eller fedme NO20092025L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85611706P 2006-11-02 2006-11-02
US11/687,945 US7763601B2 (en) 2006-11-02 2007-03-19 Prevention and treatment of obesity
PCT/HU2007/000066 WO2008053256A1 (en) 2006-11-02 2007-07-23 Reduction of overweight or obesity

Publications (1)

Publication Number Publication Date
NO20092025L true NO20092025L (no) 2009-06-02

Family

ID=38592002

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092025A NO20092025L (no) 2006-11-02 2009-05-25 Reduksjon av overvekt eller fedme

Country Status (19)

Country Link
US (1) US7763601B2 (no)
EP (1) EP2089031B1 (no)
JP (1) JP2010509199A (no)
KR (1) KR20090082442A (no)
AT (1) ATE489090T1 (no)
AU (1) AU2007315931A1 (no)
BR (1) BRPI0717867A2 (no)
CA (1) CA2668382A1 (no)
DE (1) DE602007010819D1 (no)
DK (1) DK2089031T3 (no)
HR (1) HRP20110023T1 (no)
IL (1) IL198296A (no)
MX (1) MX2009004538A (no)
NO (1) NO20092025L (no)
PL (1) PL2089031T3 (no)
PT (1) PT2089031E (no)
RU (1) RU2443417C2 (no)
SI (1) SI2089031T1 (no)
WO (1) WO2008053256A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
DE102020003608A1 (de) * 2020-06-17 2021-12-23 Bernd Clement Hemmstoffe von mARC1 zur Behandlung von Krankheiten

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187220A (en) * 1977-08-30 1980-02-05 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
US4287220A (en) * 1980-02-19 1981-09-01 Frito-Lay, Inc. Hull containing compositions
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
US6458371B1 (en) * 1995-12-22 2002-10-01 Medgene, Limited Cosmetic composition and a method for the prevention and/or reduction of the photoaging processes of the skin
US6884424B2 (en) * 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
HUP9701080A3 (en) * 1997-06-23 1999-05-28 Gene Res Lab Inc New York N Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative
AU5296799A (en) 1998-08-03 2000-02-28 N-Gene Kutato Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ
BR0210744A (pt) 2001-07-17 2004-07-20 N Gene Res Lab Inc Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes
HUP0401177A2 (en) 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition for increasing the mitochondrial genesis
HUP0401176A2 (en) 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition having prpkinetic effect
HUP0500145A2 (en) 2005-01-28 2006-11-28 Gene Res Lab N Use of o-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime for preparation of medicaments against oral diseases
CA2662337A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof

Also Published As

Publication number Publication date
BRPI0717867A2 (pt) 2013-10-29
IL198296A0 (en) 2010-02-17
EP2089031A1 (en) 2009-08-19
PL2089031T3 (pl) 2011-05-31
EP2089031B1 (en) 2010-11-24
IL198296A (en) 2011-09-27
CA2668382A1 (en) 2008-05-08
ATE489090T1 (de) 2010-12-15
KR20090082442A (ko) 2009-07-30
HK1131737A1 (en) 2010-02-05
AU2007315931A1 (en) 2008-05-08
HRP20110023T1 (hr) 2011-04-30
RU2009119567A (ru) 2010-12-10
PT2089031E (pt) 2011-02-24
DK2089031T3 (da) 2011-02-14
US20080108673A1 (en) 2008-05-08
US7763601B2 (en) 2010-07-27
WO2008053256A1 (en) 2008-05-08
DE602007010819D1 (de) 2011-01-05
SI2089031T1 (sl) 2011-04-29
MX2009004538A (es) 2009-05-22
JP2010509199A (ja) 2010-03-25
RU2443417C2 (ru) 2012-02-27

Similar Documents

Publication Publication Date Title
NO20092025L (no) Reduksjon av overvekt eller fedme
MY149853A (en) Pyridin-4-yl derivatives as immunomodulating agents
WO2008142055A3 (en) Antiviral agents
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
WO2007106670A3 (en) N-formyl hydroxylamine compounds
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
IL186349A0 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
MY153617A (en) Pyridin-4-yl derivatives
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
WO2010031184A8 (en) Azaindole derivatives as crth2 receptor antagonists
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
WO2008005651A3 (en) Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
JP2009536926A5 (no)
WO2009105969A8 (zh) 埃坡霉素类似物、其药物组合物、用途及其制备方法
DK2089032T3 (da) Farmaceutisk præparat der har antipsykotisk, antidepressiv eller antiepileptisk aktivitet med reducerede bivirkninger
NO20084543L (no) Benzimidazolderivater
IL192190A0 (en) Process for the preparation of pharmaceutical salts of 3-o-(3&#39;,3&#39;-dimethylsuccinyl) betulinic acid
NO20080035L (no) Benzooksazol-2-on derivater som lipase og fosfolipaseinhibitorer
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
NO20080034L (no) Benzotiazol-2-on derivater som lipase og fosfolipaseinhibitorer
TN2012000093A1 (en) Therapeutic agent for anxiety disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application